Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR-M61SQ Cell in Patients with Relapsed/Refractory Multiple Myeloma.

NCT06888752 is registered in ClinicalTrials.gov with First Affiliated Hospital of Wenzhou Medical University as lead sponsor.

NCT NCT06888752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06888752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR-M61SQ Cell in Patients with Relapsed/Refractory Multiple Myeloma.
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 20, 2025
Completion date
December 30, 2030
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma